<DOC>
	<DOCNO>NCT01151852</DOCNO>
	<brief_summary>The objective study compare clinical outcome follow resumption dose ( re-challenge ) Imatinib plus best supportive care versus placebo plus best supportive care patient advanced/incurable Gastrointestinal Stromal Tumors follow failure prior imatinib sunitinib therapy .</brief_summary>
	<brief_title>Rechallenge Imatinib GIST Having Effective Treatment</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients age 18 year old Patients metastatic unresectable malignant gastrointestinal stromal tumour histologically confirm detection CD117 immunohistochemical stain genetically confirm detection mutation KIT PDGFRα gene direct sequence tumor DNA . Prior benefit 1st line imatinib define complete response , partial response , stable disease 6 month start 1st line imatinib Patients whose disease progress despite least prior imatinib therapy ( 400mg/day ) subsequently also failure prior sunitinib therapy . ECOG ( Eastern Cooperative Oncology Group ) performance status 0 ~ 3 Adequate bone marrow function define platelet ≥ 75 x 109/L neutrophil ≥ 1.5 x 109/L Adequate renal function , serum creatinine &lt; 1.5 x upper limit normal Adequate hepatic function serum total bilirubin &lt; 1.5 x upper limit normal , alanine aminotransferase aspartate aminotransferase &lt; 2.5 x upper limit normal absence liver metastasis , &lt; 5 x upper limit normal presence liver metastasis . Expected life expectancy great 12 week absence intervention No malignant disease apart nonmelanotic skin cancer carcinoma situ uterine cervix cancer except treat curative intent &gt; 5 year previously without evidence relapse Written , inform consent study Medical psychiatric condition compromise patient 's ability give inform consent complete protocol history non compliance Last dose radiotherapy receive within 4 week start study treatment , exclude palliative radiotherapy Obstruction gastrointestinal tract Active gastrointestinal bleeding Myocardial infarction within 6 month prior study medication , clinically significant heart disease ( e.g. , unstable angina , congestive heart failure uncontrolled hypertension ) Evidence severe uncontrolled systemic disease concurrent condition investigator 's opinion make undesirable patient participate study would jeopardise compliance protocol Female patient pregnant breastfeeding . Female patient must negative pregnancy test within one week start imatinib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Imatinib</keyword>
	<keyword>Re-challenge</keyword>
</DOC>